Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,120.96 29.44 0.95%
FTSE 100 6,563.63 22.02 0.34%
DAX 9,249.01 75.30 0.82%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release of Clinical Data, and Obtaining Important Patents



Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release
of Clinical Data, and Obtaining Important Patents - Research Report on Galena,
                    Zalicus, Infinity, Stemline and Insmed

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 5, 2013

NEW YORK, November 5, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Galena
Biopharma, Inc. (NASDAQ: GALE), Zalicus Inc. (NASDAQ: ZLCS), Infinity
Pharmaceuticals, Inc. (NASDAQ: INFI), Stemline Therapeutics, Inc. (NASDAQ:
STML) and Insmed Incorporated (NASDAQ: INSM). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Galena Biopharma, Inc. Research Report

On September 23, 2013, Galena Biopharma, Inc. (Galena) announced the closing
of the exercise in full of the underwriters' over-allotment option to purchase
an additional 2.6 million shares of common stock of Galena. The Company
reported that the additional gross proceeds to Galena as a result of the
exercise of the option with respect to the shares are approximately $5.2
million. The net proceeds to Galena from the offering, including from the
exercise in full of the over-allotment options, are expected to be
approximately $37.6 million, after deducting underwriting discounts and
commissions and estimated offering expenses payable by Galena. The Company
stated that it intends to use the net proceeds of the offering for the
commercialization of its first commercial product, Abstral® (fentanyl)
Sublingual Tablets, other clinical trials of its product candidates, and
general corporate purposes. The Full Research Report on Galena Biopharma, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/cad6_GALE]

--

Zalicus Inc. Research Report

On September 27, 2013, Zalicus Inc. (Zalicus) announced that Z160, its
first-in-class, oral, state-dependent, selective N-type calcium channel (Cav
2.2) modulator in development for chronic neuropathic pain has received Orphan
Drug designation from the U.S. Food and Drug Administration (FDA) for the
management of postherpetic neuralgia. According to the Company, Postherpetic
neuralgia (PHN) is a painful neuropathic condition resulting from an outbreak
of the herpes zoster virus, otherwise known as shingles. Mark H.N. Corrigan,
MD, President and CEO of Zalicus commented, "The FDA's designation of Z160 as
having orphan drug status is an important milestone for Zalicus as we continue
the clinical development work required for potential FDA approval of Z160."
The Full Research Report on Zalicus Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/cbb5_ZLCS]

--

Infinity Pharmaceuticals, Inc. Research Report

On September 25, 2013, Infinity Pharmaceuticals, Inc. (Infinity) announced
topline data from its Phase 2 study of retaspimycin hydrochloride (HCl), a
potent and selective heat shock protein 90 (Hsp90) inhibitor, in patients with
non-small cell lung cancer (NSCLC) who had a history of smoking. Infinity
reported that retaspimycin HCl did not meet its pre-specified efficacy
endpoints for demonstrating an improvement in overall survival in the total
patient population or in patients with squamous cell carcinoma. "We appreciate
the support of the patients and caregivers who participated in this trial,"
stated Julian Adams, Ph.D., President of Research and Development at Infinity.
"We will now focus our clinical research and development effort on IPI-145,
our lead PI3K-delta, gamma inhibitor, for which we have encouraging data in
patients with life-threatening hematologic malignancies." The Full Research
Report on Infinity Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/3862_INFI]

--

Stemline Therapeutics, Inc. Research Report

On September 25, 2013, Stemline Therapeutics, Inc. (Stemline Therapeutics)
announced that SL-401, a Clinical-Stage Targeted Therapy, has shown
preclinical activity in an additional hematologic cancer indication, chronic
myeloid leukemia. The Company informed that SL-401 is a novel therapeutic
targeting the interleukin-3 receptor (IL-3R) that is overexpressed on the CSCs
and tumor bulk of a wide range of hematologic cancers, which is now entering
pivotal clinical trial programs in blastic plasmacytoid dendritic cell
neoplasm (BPDCN) and acute myeloid leukemia (AML), as well as clinical
evaluations in several other hematologic malignancies. The Full Research
Report on Stemline Therapeutics, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/5155_STML]

--

Insmed Incorporated Research Report

On September 11, 2013, Insmed Inc. (Insmed) announced two important patent
allowances in the U.S. and Europe that will strengthen the Company's global
patent portfolio. Insmed stated that it is focused on the development and
commercialization of ARIKACE® (liposomal amikacin for inhalation) for at least
two identified orphan patient populations: cystic fibrosis (CF) patients with
Pseudomonas aeruginosa lung infections and patients with non-tuberculous
mycobacteria (NTM) lung infections. Commenting on the patent allowances, Will
Lewis, President and CEO of Insmed said, "These new patent allowances are a
credit to our technology development team and demonstrate the inventiveness
and utility of our approach to treating serious and oftentimes
life-threatening lung diseases. As we move toward potential marketing approval
and commercialization of ARIKACE to treat Pseudomonas aeruginosa in CF
patients in Europe and Canada, and continue the clinical development of our
liposomal amikacin for inhalation to treat NTM in the U.S., these new patent
allowances provide additional protection for this valuable asset. We are
pursuing a broad intellectual property strategy that provides the foundation
to achieve our global clinical and commercial objectives and protects
shareholder value." The Full Research Report on Insmed Incorporated -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9c5b_INSM]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement